Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1951 to 1965 of 2042 results for guidelines

  1. Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

    Evidence-based recommendations on foslevodopa–foscarbidopa (Produodopa) for treating advanced Parkinson’s with motor symptoms in adults.

    Technology appraisal guidance
    Published
    29 November 2023
    View recommendations

    Sections for TA934

  2. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

    Technology appraisal guidance
    Published
    2 October 2019
    View recommendations

    Sections for TA604

  3. Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

    Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.

    Technology appraisal guidance
    Last updated
    20 November 2017
    View recommendations

    Sections for TA458

  4. Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)

    Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.

    Technology appraisal guidance
    Published
    21 December 2016
    View recommendations

    Sections for TA421

  5. Technology appraisal data

    Explore data about our technology appraisal guidance

  6. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at high risk

    based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer. There are also diagrams that...

  7. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA900

  8. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    10 May 2023
    View recommendations

    Sections for TA887

  9. The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)

    NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system

    Medtech innovation briefing
    Published
    1 February 2014

  10. Medical Technologies Evaluation Programme

    How to submit a new medical technology to NICE for guidance

  11. Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

    NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .

    Medtech innovation briefing
    Published
    18 January 2018

  12. Familial breast cancer. Patient decision aid on taking a medicine to reduce the chance of developing breast cancer for postmenopausal women at moderately increased risk

    based on the scientific evidence assessed by NICE when it produced its guideline on familial breast cancer. There are also diagrams that...

  13. Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

    Evidence-based recommendations on artificial hips and hip resurfacing for treating end-stage arthritis of the hip in adults.

    Technology appraisal guidance
    Published
    26 February 2014
    View recommendations

    Sections for TA304

  14. Models of person-centred support:- What models of delivering person-centred support are effective and cost effective for people with a learning disability and behaviour that challenges, and their families and carers?What are the views and experiences of people with a learning disability and behaviour that challenges and their family members and carers, of different models of delivering person-centred support?

    the current recommended approach and is at the centre of this service guideline. However, there is little published research about what...

    Research recommendation
    Published
    15 November 2018

  15. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

    Technology appraisal guidance
    Last updated
    13 March 2024
    View recommendations

    Sections for TA878